Heart disease is a global pandemic affecting at least 26 million people worldwide and continues to increase in prevalence due to increasing life expectancy in the general population. More effective front-line tools are needed that can assist in identifying patients earlier while also lowering costs for health systems around the world. The article is titled “Prediction of coronary artery calcium scoring from surface electrocardiogram in atherosclerotic cardiovascular disease: a pilot study”. The study evaluated the feasibility of MyoVista Technology to assist in predicting abnormal calcium scores.
Study demonstrates MyoVista® wavECG™ ability to cost-effectively detect LV Dysfunction SOUTHLAKE, Texas, August 18, 2020 – HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced today the results of a multicenter prospective study conducted at 4 centers in North America enrolling a total of 1,202 subjects. The study […]
HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced submission to the U.S. FDA via De Novo premarket review pathway for the MyoVista Wavelet ECG (wavECG) Cardiac Testing Device. The De Novo pathway is used for novel medical devices that are low to moderate risk. Mark Hilz “HeartSciences seeks […]
12 lead ECG device detects LV relaxation impairment associated with Left Ventricular Diastolic Dysfunction SOUTHLAKE, TEXAS – December 9, 2019 – HeartSciences, a medical device company focused on advancing the field of electrocardiology through innovation, announced submission to the U.S. Food and Drug Administration (FDA) via De Novo premarket review pathway for the MyoVista® […]
HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine Southlake, Texas – Silicon Review, a leading Business and Technology magazine has named HeartSciences, as one of the 50 Smartest Companies of the Year 2018. “The Silicon Review 50 Smartest Companies of the Year 2018 program identifies companies that mastered […]
HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC) Hall A, Booth G320 SOUTHLAKE, Texas, August 20, 2018 –(BUSINESSWIRE)—HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence is proud to announce its participation as an exhibitor at the upcoming […]
SOUTHLAKE, Texas, June 25, 2018 –(BUSINESSWIRE)—HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018.
HeartSciences: AI Improves Frontline Risk Stratification for Heart Diseases
HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today that Peter W. Macfarlane has joined its board of clinical advisors.
“These positive results demonstrate that MyoVista wavECG Technology, which includes our patented signal processing methods combined with artificial intelligence, can lead to enhanced capabilities and completely new uses for electrocardiography-based (ECG) devices”
SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 China International Medicinal Equipment Fair (CMEF) Shanghai, China, April 11-14, 2018. CMEF has become the largest fair of medical devices, related products and services in the Asia-Pacific region. The fair widely covers 15,000 products, almost 4,200 medical device manufacturers from over 28 countries, and about 120,000 visitors and buyers who are government procurement agencies, hospital buyers and dealers.
Poster Title: Prediction of Cardiac Mechanical Relaxation Abnormalities from Surface ECG Wavelets Date: Sunday, March 11, 2018 at 3:45 p.m. Location: Orange County Convention Center | 9800 International Drive | Orlando, Florida 32819 USA | Hall A/B Poster: 1238-107 HeartSciences will participate in the Future Hub at ACC 2018. Future Hub is a multi-vendor educational […]
Photos taken at the International Modern Hospital in Dubai where MyoVista was used during the Preventative Health Camp for the employees of Emirates NBD Bank.
Southlake, Texas – January 3, 2018 – HeartSciences, a medical device company recently selected as a finalist for the Digital Health Solution category of Fierce Innovation Awards will be presenting in San Francisco at the BioTech Showcase. Tuesday, January 9 at the BioTech Showcase at 2:45pm at the Hilton Hotel, Union Square and Wednesday, January 10 at the Digital Medicine and Technology Showcase at 10.00am, at the Parc 55 Hotel.
HeartSciences and MyoVista Cardiac Testing Device http://windsor.ctvnews.ca/video?clipId=1243217&binId=1.1143900&playlistPageNum=1
US-based medical device developer HeartSciences has launched its MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device in Europe after receiving CE-Mark. MyoVista is intended to provide an effective, low-cost, front-line screening solution for cardiac disease in symptomatic as well as asymptomatic patients. Click here for full story
It’s no secret that both Apple and Google have their sights set on the healthcare market. Both have gradually become more involved with health-focused projects – the latter investing heavily in its life sciences division, Verily, and the former striking deals with health firms in its trademark covert fashion. Click here for the full story
European regulators gave HeartSciences CE mark approval for its MyoVista high sensitivity electrocardiograph testing device, a technology that uses Continuous Wavelet Transform to measure cardiac energy per heartbeat. The device, which is a combination of traditional 12-lead resting ECG tracings, ECG interpretive analysis and informatics, has also been launched by the company in Europe. Click […]
HeartSciences said today that its MyoVista high sensitivity electrocardiograph testing device won CE Mark and launched in Europe. The Westlake, Texas.-based company’s device measures the heart’s energy per heartbeat using Continuous Wavelet Transform, a type of advanced signal processing that provides doctors with a detailed visual description of a cardiac cycle’s energy distribution. Click here […]
European cardiologists may soon be able to detect the presence of heart disease more effectively in patients, thanks to a new advanced ECG tool. HeartSciences’ MyoVista high-sensitivity electrocardiograph (hsECG) Testing Device is now available for sale and distribution in markets across the European Union, following CE approval. Click here for the story
HeartSciences has started selling its MyoVista electrocardiograph (ECG) in Europe after picking up a CE mark. The device is designed to enable early detection of artery disease by visualizing energy distribution during cardiac cycles. Traditional ECGs detect and display the electrical signals the heart produces when it beats. The low cost and safety of the […]
HeartSciences is a medical device company with the mission to enable accurate, affordable screening for the early detection of heart disease. Our groundbreaking MyoVista® high-sensitivity ECG (hsECGTM) device advances the field of cardiac testing by filling the “diagnostic gap” in cardiac care and detecting cardiac dysfunction even in asymptomatic stages.
HeartSciences, a firm based outside of Dallas, Texas, is releasing in Europe its MyoVista high sensitivity electrocardiograph (hsECG) device that helps to screen patients for cardiac disease. It relies on a mathematical method known as continuous wavelet transform to process ECG data in a manner very different than conventional ECG. The company compares the way its MyoVista’s […]